IDH2 deficiency impairs mitochondrial function in endothelial cells and endothelium-dependent vasomotor function.

Area of Science:

• Biochemistry
• Cell Biology
• Vascular Biology

Background:

• Mitochondrial NADP(+)-dependent isocitrate dehydrogenase (IDH2) is crucial for cellular protection against oxidative stress.
• IDH2 deficiency causes mitochondrial dysfunction and reactive oxygen species (ROS) production in various cell types.
• The role of IDH2 in vascular endothelial cells remains largely unexplored.

Purpose of the Study:

• To investigate the impact of IDH2 deficiency on mitochondrial and vascular function in endothelial cells.
• To elucidate the mechanisms underlying IDH2 deficiency-induced endothelial dysfunction.

Main Methods:

• IDH2 knockdown in endothelial cells.
• Assessment of mitochondrial oxidative phosphorylation (OXPHOS) complexes, mitochondrial superoxide production, and mitochondrial fission-fusion proteins (Mfn-1, OPA-1, Drp-1).
• Measurement of manganese superoxide dismutase (MnSOD) expression, endothelial nitric oxide synthase (eNOS) phosphorylation, and nitric oxide (NO) concentration.
• In vivo studies using IDH2 knockout mice to assess endothelium-dependent vasorelaxation and NO bioavailability.
• Treatment with Mito-TEMPO, a mitochondrial superoxide scavenger.

Main Results:

• IDH2 knockdown reduced OXPHOS complexes I, II, and III, leading to increased mitochondrial superoxide.
• IDH2 deficiency altered mitochondrial fission-fusion protein levels and decreased MnSOD expression.
• Endothelial IDH2 knockdown reduced eNOS phosphorylation and NO concentration, effects partially reversed by Mito-TEMPO.
• Mito-TEMPO treatment restored mitochondrial dynamics, reduced superoxide, and improved MnSOD expression, eNOS phosphorylation, and NO production.
• IDH2 knockout mice exhibited impaired endothelium-dependent vasorelaxation and decreased bioavailable NO.

Conclusions:

• IDH2 deficiency induces endothelial dysfunction.
• This dysfunction is mediated by mitochondrial dynamic alterations, increased oxidative stress, and impaired NO signaling.
• Targeting mitochondrial superoxide production may offer a therapeutic strategy for IDH2-related endothelial dysfunction.